Consequently, the combined administration of PPARγ antagonists and ICB therapy proves effective in inhibiting liver cancer resistance to ICB, mediating the normalization of the tumor microenvironment (TME), and contributing to cancer treatment [147]. This evidence concerns the gene PPARG and liver cancer.